Molecular Profiling of Low-Risk Papillary Thyroid Carcinoma (mPTC) on Active Surveillance
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgae575 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Teresa Ramone und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa 56124, Italy. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Thyroid Cancer, Papillary, Watchful Waiting, Biomarkers, Tumor. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: European Union-NextGenerationEU, Italian Ministry of University and Research, European Union or the European Commission.
Abstract (Originalsprache)
Context
The active surveillance (AS) program for papillary thyroid carcinoma (≤1 cm) at low risk (mPTC) showed a low percentage of progression.
Objective
The aim of this study was to find a molecular signature of cases that showed disease progression during AS, which would allow their early identification.
Methods
We performed next-generation sequencing of 95 fine-needle aspiration cytology specimens from cases prospectively enrolled in the AS program to analyze key somatic driver alterations or gene fusions implicated in PTC tumorigenesis. TERT promoter analysis was performed using Sanger sequencing or droplet digital polymerase chain reaction.
Results
BRAF p.V600E was found in 66.3% (63/95) of mPTC and was the most common somatic alteration, followed by RAS oncogene mutations detected in 3.2% of mPTC (3/95: 2 NRAS and 1 KRAS) and gene fusions detected in 3.2% of mPTC (3/95: 1 RET-PTC1, 1 TFG-NTRK1, 1 ALK imbalance). No TERT promoter mutations (C228T and C250T) were found in the analyzed mPTC (84/95). The comparison between the molecular profile and the clinical outcome of the mPTC (stable vs progressive disease) showed no correlation (P = .6) and did not identify a molecular signature able to identify progressive mPTC.
Conclusion
The molecular profile of mPTC is like that of bigger PTC with the exception that none of them showed a TERT promoter mutation. The identification of the most common driver mutations, such as BRAF, RAS, or gene fusions, is not helpful for the early identification of mPTC that will show disease progression during follow-up in the AS program.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa 56124, Italy.
- Department of Information Engineering, University of Pisa, Pisa 56124, Italy.
- Department of Surgical, Medical and Molecular Pathology, University of Pisa, Pisa 56124, Italy.
ORCID-Profile: Antonio Matrone, Raffaele Ciampi, Cristina Romei, Rossella Elisei
Förderung
- European Union-NextGenerationEU
- Italian Ministry of University and Research
- European Union or the European Commission
- Ministero dell'Istruzione, dell'Università e della Ricerca
- European Union—NextGenerationEU
- Ministero dell’Istruzione, dell’Università e della Ricerca
Zitieren
APA
Ramone, T., Ghirri, A., Prete, A., Matrone, A., Ciampi, R., Piaggi, P., Scutari, M., Rago, T., Torregrossa, L., Romei, C., Elisei, R., & Molinaro, E. (2025). Molecular Profiling of Low-Risk Papillary Thyroid Carcinoma (mPTC) on Active Surveillance. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae575
Vancouver
Ramone T, Ghirri A, Prete A, Matrone A, Ciampi R, Piaggi P, et al. Molecular Profiling of Low-Risk Papillary Thyroid Carcinoma (mPTC) on Active Surveillance. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae575
BibTeX
@article{Ramone2025,
author = {Ramone, Teresa and Ghirri, Arianna and Prete, Alessandro and Matrone, Antonio and Ciampi, Raffaele and Piaggi, Paolo and Scutari, Maria and Rago, Teresa and Torregrossa, Liborio and Romei, Cristina and Elisei, Rossella and Molinaro, Eleonora},
title = {Molecular Profiling of Low-Risk Papillary Thyroid Carcinoma (mPTC) on Active Surveillance},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgae575}
}
EUVIMED